Download File - JOHN J. HADDAD, Ph.D.

More documents

Recommendations

Info

Index 209 DC. See Dendritic cells (DC) DC-based immunotherapy, for gliomas acid-eluted autologous tumor peptides in, 92–93 CTL assays in, 93 DC-glioma fusion cell vaccine, 91 future strategies for, 98–99 CD8 þ RTEs in, 104 CSC in, 99 summary of clinical trials, 100–103 TIL and, 93–94 tumor lysate-pulsed DC, 89–91 intradermal vaccination of, 91–92 DC-glioma fusion cell vaccine, 91 Delayed type hypersensitivity (DTH), 58, 59 Dendritic cells (DC), 86, 119, 121, 135 autologous, 71, 74 cathepsin S in, 8 in CD8 þ -cell priming, 19–20 GILT expression in, 9 immunotherapy for gliomas (See DC-based immunotherapy, for gliomas) long peptides processing by, 15–16 proteasomes of, 19 proteins at surface of, 11 states of, 19 subset, 19 therapy, 71 vaccines for gliomas (See DC-based immunotherapy, for gliomas) Dermis. See Dendritic cells (DCs) Devitalization process, 73 DFS. See Disease-free survival (DFS), in cancer patients Disease-free survival (DFS), in cancer patients, 58 D122 lung cancer cells, 37 DNA immunization, 132–135 DNA sequences, 134, 137 DNA vaccines advantages of, 135–137 immunization of, 132–135 prime-boost strategies for, 137–141 strategies to improve, 141–145 Docetaxel, 41 Drugs development. See also Investigational drugs conventional approach in, 177–178 epitope targeted approach in, 168 innovative technologies in, 175 investigational data analysis in, 176–177 linear process of, 153 molecular targeted therapies for, 152 optimized approach of, 177 preclinical and clinical models for, 154–164 second- and third-generation of, 176 translational approach in, 169–175 DTH. See Delayed type hypersensitivity (DTH) E75. See HER2/neu peptide vaccine (E75) EGFP-Ub, detection of, 15 Electroporation, 139–140 ELISA assay, 118, 120. See also ELISPOT assay ELISPOT assay, 194 monitoring of MKC1106-PP, 195 Endo/lysosomal enzymes, 7–8 Endosomal maturation, stages of, 8 Endpoints, clinical, 152 Epitope targeted approach, hypothetical, 168 ERAAP in mice, 6–7 Favld, 75 FDA. See Food and Drug Administration (FDA) FFPE. See Formalin-fixed paraffin-embedded (FFPE) flt3 ligand, 121 Fluorophores, organic and inorganic, 188 Follicular B-cell non-Hodgkin’s lymphoma, 75 Food and Drug Administration (FDA), United States, 196–197 Formalin-fixed paraffin-embedded (FFPE), tumor samples detection of mRNA, 184
210 Index Freund’s adjuvants. See Incomplete Freund’s adjuvant (IFA) Gangliosides, 111 expression of, 58 Gardasil, 56, 60 GBM. See Glioblastoma multiforme (GBM) Gene gun, 134, 143 Genomic instability, in tumors, 182 Genotyping, 189–191 for HIV infections, 197 GILT. See IFN-g–inducible lysosomal thiol reductase (GILT) Gleevec, 69 Glioblastoma multiforme (GBM), 83. See also Gliomas immunotherapy for (See DC-based immunotherapy) impaired immune function, 87–88 Gliomas and chemotherapy resistance, 94 sensitization, 94–96 DC-based immunotherapy for acid-eluted autologous tumor peptides in, 92–93 CTL assays in, 93 DC-glioma fusion cell vaccine, 91 future strategies for, 98–99, 104 summary of clinical trials, 100–103 TIL and, 93–94 tumor lysate-pulsed DC, 89–92 impaired immune function and, 87–88 GM-CSF. See Granulocyte-macrophage colony-stimulating factor (GM-CSF) gp100 peptides, 112 optimization of, 118 vs. tyrosinase peptides, 120 G-protein signaling 5 (RGS5), regulator of, 111 Granulocyte-macrophage colonystimulating factor (GM-CSF), 37 cytokine, 59–60, 74, 75 GSK 1572932A, 76 GVAX, phase 3 trials with, 56 Hapten, 37 Hapten-modified autologous tumor cells, 45 Heat shock protein–peptide complexes (HSPPC), 73 tumor derived, 33–37 Heat shock proteins (HSP) chaperone function of, 33 complexes of, 73 tumor-derived, 33 polypeptide complexes, 133, 134 role of, 33 Hematologic malignancies, 111 Hepatitis B virus, vaccine for, 137 HercepTest, 196 Herceptin, 69, 196 HER2/neu peptide vaccine (E75), 111 for breast carcinoma, 166 vaccination with, 121 HIV cancer in patient with, 70 genotyping for, 197 vaccines for, 138 HIV-Nef-derived peptide, 6 HLA, 84, 87–88 molecules antigens derived from, 110–111 peptide vaccines of, 117–122 HLA-A3, 6 HLA-A11, 6 HLA-A*0201 allele, 189 HLA-A2-restricted peptide tumor antigen MAGE-3 271–279, 13, 15 HLA-G expression, 88 HLA markers. See B2M HLA1 molecules genotyping of, 189–191 IHC detection of, 187 peptide complexes of, 182, 183 HLA transgenic mice, 155 Hormonal therapeutics, 55 Hormone refractory prostate cancer (HRPC), metastatic, 117 HPV. See Human papillomavirus (HPV) HSP. See Heat shock protein (HSP); Heat shock proteins (HSP) hTRT. See Human telomerase reverse transcriptase (hTRT) Human leukocyte antigens (HLA). See HLA
Page 1 and 2:
Translational Medicine Series 6 Can
Page 3 and 4:
TRANSLATIONAL MEDICINE SERIES 1. Pr
Page 5 and 6:
Informa Healthcare USA, Inc. 52 Van
Page 8 and 9:
Preface Throughout the last 20 year
Page 10 and 11:
Preface vii Table 1 A Diverse Techn
Page 12 and 13:
Preface . . . . v Contributors . .
Page 14 and 15:
Contributors Pedro Alves Ludwig Ins
Page 16 and 17:
1 Factoring in Antigen Processing i
Page 18 and 19:
Factoring in Antigen Processing in
Page 20 and 21:
Page 22 and 23:
Page 24 and 25:
Page 26 and 27:
Page 28 and 29:
Page 30 and 31:
Page 32 and 33:
Page 34 and 35:
Page 36 and 37:
Page 38 and 39:
Page 40 and 41:
Page 42 and 43:
Page 44 and 45:
Page 46 and 47:
2 Outlining the Gap Between Preclin
Page 48 and 49:
Preclinical Models and Clinical Sit
Page 50 and 51:
Table 1 Examples of Preclinical Act
Page 52 and 53:
Page 54 and 55:
Page 56 and 57:
Page 58 and 59:
Page 60 and 61:
Page 62 and 63:
Page 64 and 65:
Page 66 and 67:
Page 68:
Page 71 and 72:
56 Srinivasan disease agents. Garda
Page 73 and 74:
58 Srinivasan expressing various kn
Page 75 and 76:
60 Srinivasan The above-mentioned a
Page 77 and 78:
62 Srinivasan (69). In another stud
Page 79 and 80:
64 Srinivasan patients with prostat
Page 81 and 82:
66 Srinivasan 33. Salgia R, Lynch T
Page 83 and 84:
68 Srinivasan 67. Werness BA, Levin
Page 85 and 86:
70 Teofilovici and Wentworth In 190
Page 87 and 88:
72 Teofilovici and Wentworth conduc
Page 89 and 90:
74 Teofilovici and Wentworth Lipono
Page 91 and 92:
76 Teofilovici and Wentworth (best
Page 93 and 94:
78 Teofilovici and Wentworth nature
Page 95 and 96:
80 Teofilovici and Wentworth In the
Page 97 and 98:
82 Teofilovici and Wentworth 17. Ba
Page 99 and 100:
84 Luptrawan et al. Dendritic cells
Page 101 and 102:
86 Luptrawan et al. of cancer cells
Page 103 and 104:
88 Luptrawan et al. NK cells can ki
Page 105 and 106:
90 Luptrawan et al. Figure 2 Repres
Page 107 and 108:
92 Luptrawan et al. state (50). Pat
Page 109 and 110:
94 Luptrawan et al. ability of TIL
Page 111 and 112:
96 Luptrawan et al. Figure 4 Drug s
Page 113 and 114:
98 Luptrawan et al. Figure 6 Tumor
Page 115 and 116:
Table 1 Summary of results of phase
Page 117 and 118:
102 Luptrawan et al. Table 1 Summar
Page 119 and 120:
104 Luptrawan et al. antigens (84,8
Page 121 and 122:
106 Luptrawan et al. 30. Ranges GE,
Page 123 and 124:
108 Luptrawan et al. 66. Dunn GP, B
Page 125 and 126:
110 Schroter and Minev proteins (2,
Page 127 and 128:
112 Schroter and Minev tumor-challe
Page 129 and 130:
114 Schroter and Minev Table 1 Inve
Page 131 and 132:
116 Schroter and Minev Table 1 Inve
Page 133 and 134:
118 Schroter and Minev demonstrated
Page 135 and 136:
120 Schroter and Minev loaded MART-
Page 137 and 138:
122 Schroter and Minev illustrate t
Page 139 and 140:
124 Schroter and Minev 4. Heemels M
Page 141 and 142:
126 Schroter and Minev 42. Minev BR
Page 143 and 144:
128 Schroter and Minev 74. Restifo
Page 146 and 147:
7 Multimodality Immunization Approa
Page 148 and 149:
Multimodality Immunization Approach
Page 150 and 151:
Page 152 and 153:
Page 154 and 155:
Page 156 and 157:
Page 158 and 159:
Page 160 and 161:
Page 162 and 163:
Figure 5.1 Immunohistochemical char
Page 164 and 165:
Figure 8.5 A schematic representati
Page 166 and 167:
Page 168 and 169:
Page 170 and 171:
8 Bidirectional Bedside Lab Bench P
Page 172 and 173:
Development of Novel Immunotherapeu
Page 174 and 175:
Page 176 and 177:
Page 178 and 179: Development of Novel Immunotherapeu
Page 200 and 201: 9 Diagnostic Approaches for Selecti
Page 202 and 203: Diagnostic Approaches to Maximize T
Page 222: Diagnostic Approaches to Maximize T
Page 225 and 226: 206 Index Antigenic peptides degrad
Page 227: 208 Index Chromogens, enzymatic act
Page 231 and 232: 212 Index Langerhans cells, 133, 13
Page 233 and 234: 214 Index [Peptide vaccines] invest
Page 235 and 236: 216 Index TCRL. See TCR-like immuno
Page 238: Oncology and Immunology about the b
show all

Download File - JOHN J. HADDAD, Ph.D.

You also want an ePaper? Increase the reach of your titles

Delete template?

Save as template?